RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Paradigm Biopharmaceuticals Stock

Paradigm Biopharmaceuticals Stocks 2025

Paradigm Biopharmaceuticals Stocks

389.43 M

Ticker

PAR.AX

ISIN

AU000000PAR5

In 2025, Paradigm Biopharmaceuticals had 389.43 M outstanding stocks, a 11.15% change from the 350.36 M stocks in the previous year.

The Paradigm Biopharmaceuticals Stocks history

YEARNUMBER OF STOCKS (M AUD)
2028e389.43
2027e389.43
2026e389.43
2025389.43
2024350.36
2023289.67
2022240.95
2021212.18
2020202.56
2019144.08
2018117.01
201798.58
201683.18
201547.69
201447.69

Paradigm Biopharmaceuticals shares outstanding

The number of shares was Paradigm Biopharmaceuticals in 2024 — This indicates how many shares 350.364 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Paradigm Biopharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Paradigm Biopharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Paradigm Biopharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Paradigm Biopharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Paradigm Biopharmaceuticals Aktienanalyse

What does Paradigm Biopharmaceuticals do?

Paradigm Biopharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Paradigm Biopharmaceuticals's Shares Outstanding

Paradigm Biopharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Paradigm Biopharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Paradigm Biopharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Paradigm Biopharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Paradigm Biopharmaceuticals stock

How many stocks are there of Paradigm Biopharmaceuticals?

The current number of stocks of Paradigm Biopharmaceuticals is 389.43 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Paradigm Biopharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Paradigm Biopharmaceuticals evolved in recent years?

The number of shares of Paradigm Biopharmaceuticals has increased by 11.15% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Paradigm Biopharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Paradigm Biopharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Paradigm Biopharmaceuticals pay?

Over the past 12 months, Paradigm Biopharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Paradigm Biopharmaceuticals is expected to pay a dividend of 0 AUD.

What is the dividend yield of Paradigm Biopharmaceuticals?

The current dividend yield of Paradigm Biopharmaceuticals is .

When does Paradigm Biopharmaceuticals pay dividends?

Paradigm Biopharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Paradigm Biopharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Paradigm Biopharmaceuticals located?

Paradigm Biopharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Paradigm Biopharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Paradigm Biopharmaceuticals from 10/9/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/9/2025.

When did Paradigm Biopharmaceuticals pay the last dividend?

The last dividend was paid out on 10/9/2025.

What was the dividend of Paradigm Biopharmaceuticals in the year 2024?

In the year 2024, Paradigm Biopharmaceuticals distributed 0 AUD as dividends.

In which currency does Paradigm Biopharmaceuticals pay out the dividend?

The dividends of Paradigm Biopharmaceuticals are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Paradigm Biopharmaceuticals

Our stock analysis for Paradigm Biopharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Paradigm Biopharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.